Pilot study to enhance HIV care using needle exchange-based health services for out-of-treatment injecting drug users

被引:57
作者
Altice, FL [1 ]
Springer, S [1 ]
Buitrago, M [1 ]
Hunt, DP [1 ]
Friedland, GH [1 ]
机构
[1] Yale Univ, AIDS Program, New Haven, CT 06510 USA
来源
JOURNAL OF URBAN HEALTH-BULLETIN OF THE NEW YORK ACADEMY OF MEDICINE | 2003年 / 80卷 / 03期
关键词
adherence; antiretroviral therapy; directly observed therapy; health care; injecting drug users; intervention; HIV/AIDS; HIV therapeutics; needle exchange; substance abuse; substance abuse treatment;
D O I
10.1093/jurban/jtg053
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
The introduction of highly active antiretroviral therapy (HAART) has resulted in marked reductions in mortality and acquired immunodeficiency syndrome (AIDS) incidence across all risk groups; however, the proportionate decrease among injecting drug users (IDUs) has been less impressive. Much of the disparity in benefit to IDUs has been a consequence of decreased access to and receipt of potent antiretroviral combinations. Strategies to increase access to and utilization of HAART have included entry into drug treatment and abstinence. Unfortunately, as few as 15%-20% of active drug users in the United States, and in many other countries, are in drug treatment at any one time. We report a pilot project among out-of-drug treatment ID Us infected with human immunodeficiency virus. (HIV); HIV therapy was successfully provided to active heroin injectors using. the Community Health Care Van (CHCV) at sites of needle exchange. Subjects were willing to initiate, but were not receiving, recommended HIV therapy and were not interested in formal drug treatment. Antiretroviral therapy regimens were selected and linked to heroin injection timing. Weekly visits were scheduled by CHCV staff to assess adverse side effects and encourage adherence. Of the 13 participants, the mean baseline HIV-1 RNA level and CD4 lymphocyte count were 162,369 (log 5.21) copies per milliliter and 265 cells per milliliter, respectively. By 6 months, the proportion whose HIV-1 RNA was below the limits of detection (<400 copies/mL) was 85% (N = 11); 77% (N = 10) had nondetectable levels by 9 months. By 12 months, 54% (N = 7) had a persistently nondetectable viral load, and the net increase in CD4 lymphocyte count was 150 cells per milliliter. As an additional and unintended benefit of this pilot project, 9 (69%) subjects chose to enter drug treatment after achieving a nondetectable viral load. Entry into drug treatment was associated with durability of viral suppression. This small pilot study suggests that health services based on needle exchange may enhance access to HAART among out-of-treatment HIV-infected IDUs. In addition, it demonstrates that this,Population can benefit from this therapy with the support of a nontraditional, community-based health intervention.
引用
收藏
页码:416 / 427
页数:12
相关论文
共 60 条
[1]   Basic need status and health-promoting self-care behavior in adults [J].
Acton, GJ ;
Malathum, P .
WESTERN JOURNAL OF NURSING RESEARCH, 2000, 22 (07) :796-811
[2]  
Altice FL, 2001, J ACQ IMMUN DEF SYND, V28, P47, DOI 10.1097/00042560-200109010-00008
[3]  
[Anonymous], AIDS READ
[4]   Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: Comparison of self-report and electronic monitoring [J].
Arnsten, JH ;
Demas, PA ;
Farzadegan, H ;
Grant, RW ;
Gourevitch, MN ;
Chang, CJ ;
Buono, D ;
Eckholdt, H ;
Howard, AA ;
Schoenbaum, EE .
CLINICAL INFECTIOUS DISEASES, 2001, 33 (08) :1417-1423
[5]   Directly observed therapy to treat HIV infection in prisoners [J].
Babudieri, S ;
Aceti, A ;
D'Offizi, GP ;
Carbonara, S ;
Starnini, G .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 284 (02) :179-180
[6]   Helping the urban poor stay with antiretroviral HIV drug therapy [J].
Bamberger, JD ;
Unick, J ;
Klein, P ;
Fraser, M ;
Chesney, M ;
Katz, MH .
AMERICAN JOURNAL OF PUBLIC HEALTH, 2000, 90 (05) :699-701
[7]  
Barry M, 1994, Conn Med, V58, P535
[8]   Antiretroviral therapy for HIV infection in 1997 - Updated recommendations of the International AIDS Society USA panel [J].
Carpenter, CCJ ;
Fischl, MA ;
Hammer, SM ;
Hirsch, MS ;
Jacobsen, DM ;
Katzenstein, DA ;
Montaner, JSG ;
Richman, DD ;
Saag, MS ;
Schooley, RT ;
Thompson, MA ;
Vella, S ;
Yeni, PG ;
Volberding, PA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (24) :1962-1969
[9]   Self-reported antiretroviral therapy in injection drug users [J].
Celentano, DD ;
Vlahov, D ;
Cohn, S ;
Shadle, VM ;
Obasanjo, O ;
Moore, RD .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (06) :544-546
[10]   Medication adherence among HIV-infected patients: Understanding the complex behavior of patients taking this complex therapy [J].
Laura W. Cheever ;
Albert W. Wu .
Current Infectious Disease Reports, 1999, 1 (4) :401-407